Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
- Update frequency
- every day
- Average duration
- 26 minutes
- Episodes
- 1069
- Years Active
- 2020 - 2025
S2-E49.2 - Clinical Care Pathway: Behavior Change and Prevalence Data
Last author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green to discuss the recent Clinical Care Pathway p…
S2-E49.1 - Clinical Care Pathway: How It Came To Be
Last author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green to discuss the recent Clinical Care Pathway p…
S2-E49 - Finally, a Clinical Care Pathway For a Hidden Pandemic!
Last author and leading endocrinology Fatty Liver Opinion Leader Ken Cusi joins co-author Stephen Harrison, Louise Campbell and Roger Green to discuss the recent Clinical Care Pathway p…
S2-E48.4 - Closing Thoughts On Summer: What Mattered Most?
Mazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of "Biggest Stories of NASH Summer." In this conversation, Roger uses a classical Marketing R…
S2-E48.3 - Closing thoughts on Summer: Looking From a Patient-Based Perspective
Mazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of "Biggest Stories of NASH Summer." In this conversation, Louise Campbell raises two very di…
S2-E48.2 - Closing Thoughts On Summer: More on FGF-21s and A Topical "Hijacking"
Mazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of "Biggest Stories of NASH Summer." In this conversation, Stephen Harrison starts by discuss…
S2-E48.1 - Closing Thoughts On Summer: Mazen Noureddin's Two Big Things
Mazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of "Biggest Stories of NASH Summer." In this conversation, Stephen Harrison provides an image…
S2-E48 - Closing Thoughts On an Eventful NASH Summer
Mazen Noureddin joins Stephen Harrison, Louise Campbell and Roger Green to close our series of "Biggest Stories of NASH Summer" with his own unique slant on recent events and publicatio…
S2-E47.3 - Most Important Story of Summer? Manal Abdelmalek Says, "NIH Funding Liver Cirrhosis Network"
Professor Manal Abdelmalek joins Louise Campbell and Roger Green to discuss the important Fatty Liver stories of the last few months. She focuses on NIH's recent decision to stand up an…
S2-E47.2 - Most Important Story of Summer? Michelle Long Says, "Harrison/Alkhouri Prevalence Paper."
Professor and epidemiologist Michelle Long joins Louise Campbell and Roger Green to discuss the important Fatty Liver stories of the last few months. She focuses on the recent paper on …
S2-E47.1 - Most important Story of Summer? Ian Rowe says, "FDA ELF Approval."
Newly-appointed Professor Ian Rowe joins Louise Campbell and Roger Green to discuss the important Fatty Liver stories of the last few months. He focuses on the recent FDA approval of th…
S2-E47 - Ask Opinion Leaders: The Biggest NAFLD/NASH Stories of Summer
Ian Rowe, Michelle Long and Manal Abdelmalek reveal what they consider the most important NAFLD/NASH stories of summer.
Which NAFLD/NASH stories did they choose? The newly-appointed Prof…
S2-E46.3 - Top Stories From Paris NASH: Connecting the Dots
Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week's Paris NASH meeting. This conversation looks at the Day Two sessions and the overall i…
S2-E46.1 - Top stories from Paris NASH: Epidemiology and Clinical Aspects
Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week's Paris NASH meeting. This conversation looks at sessions covering epidemiology, public…
S2-E46.2 - Top Stories From Paris NASH: Deep Dive into Fibrosis
Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week's Paris NASH meeting. This conversation looks at the session covering fibrosis.
Paris NA…
S2-E46 - Highlights from Paris NASH
Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week's Paris NASH meeting, an event with exciting scientific messages and insights.
If you mi…
S2-E45.3 - Discussing the EASL Guidelines and the Path to A Non-Invasive Testing Future with Donna Cryer
Global Liver Institute President and CEO Donna Cryer joins Roger Green to discuss why recent EASL guidelines around use of non-invasive tests (NITs) in Fatty Liver diagnosis and disease…
S2-E45.2 - Discussing Non-Invasive Testing and the Patient Experience with Wayne Eskridge.
Fatty Liver Foundation President Wayne Eskridge joins Louise Campbell and Roger Green to discuss why he is so enthusiastic about the FDA's recent approval of the ELF test as a prognosti…
S2-E45.1 - Discussing Fatty Liver Disease Prevalence And Patient Awareness With Anthony Villiotti
NASH kNOWledge President Anthony Villiotti joins Louise Campbell and Roger Green to highlight two recent publications about NAFLD/NASH prevalence (underestimated!) and patient awareness…
S2-E45 - Ask the Advocates: The Biggest NAFLD/NASH Story of the Summer
Louise Campbell and Roger Green interview patients/patient advocates Donna Cryer, Wayne Eskridge and Anthony Villiotti about what each considers the biggest NAFLD story of the summer.
Th…